Publications

Early-onset pancreatic cancer research: making sense of confounding and bias →

Miksad, RA, Calip, GS

September 2021

Manuscript

Cancer

Flatiron-authored

Dosing schedules of Gemcitabine and nab-Paclitaxel for older adults with metastatic pancreatic cancer →

Winer, A, Handorf, E, Dotan, E

August 2021

Manuscript

JNCI Cancer Spectrum

Real-world serum CA19-9 level monitoring patterns and its association with clinical outcomes among patients with metastatic pancreatic ductal adenocarcinoma →

George, B, Kent, M, Surinach, A, Lamarre, N, Cockrum, P, Chudnovsky, A

April 2021

Abstract

AACR Annual Meeting

The incidence of thrombocytopenia in adult patients receiving chemotherapy for solid tumors or hematologic malignancies →

Shaw, JL, Nielson, CM, Park, JK, Marongiu, A, Soff, GA

February 2021

Manuscript

European Journal of Haematology

Real-world outcomes associated with liposomal irinotecan dose reductions in metastatic pancreatic ductal adenocarcinoma →

Abushahin, LI, Cockrum, P, Surinach, A, Belanger, B

October 2020

Manuscript

Future Oncology

Reducing nihilism in metastatic pancreatic ductal adenocarcinoma: treatment, sequencing, and effects on survival outcomes →

O'Reilly, EM, Cockrum, P, Surinach, A, Wu, Z, Dillon, A, Yu, KH

September 2020

Manuscript

Cancer Medicine

Trends in real-world clinical outcomes among patients with metastatic pancreatic adenocarcinoma treated with liposomal irinotecan based regimens in the United States →

Koeller, J, Cockrum, P, Belanger, B, Corvino, FA, Surinach, A, Kim, GP

May 2020

Abstract

ASCO Annual Meeting

Real-world use of liposomal irinotecan-based regimens among patients with metastatic pancreatic adenocarcinoma in the United States →

Kim, GP, Cockrum, P, Surinach, A, Koeller, J

May 2020

Abstract

ASCO Annual Meeting

Real-world dosing, management, and clinical outcomes of patients with metastatic pancreatic adenocarcinoma treated with liposomal irinotecan →

Abushahin, LI, Cockrum, P, Surinach, A, Belanger, B

May 2020

Abstract

ASCO Annual Meeting

Real-world dosing patterns and outcomes of patients with metastatic pancreatic cancer treated with a liposomal irinotecan regimen in the United States →

Barzi, A, Miksad, RA, Surinach, A, Corvino, FA, Wang, S, Torres, AZ, Mamlouk, K, Pulgar, S, Valderrama, A, Bekaii-Saab, T, Ahn, D

January 2020

Manuscript

Pancreas

Flatiron-authored

Impact of dose reductions on clinical outcomes among patients (pts) with metastatic pancreatic cancer (mPC) treated with liposomal irinotecan (nal-IRI) in oncology clinics in the United States →

Cockrum, P, Surinach, A, Kim, GP, Mercer, D, Koeller, J, Miksad, RA

January 2020

Abstract

ASCO GI Symposium

Flatiron-authored

Survival outcomes based on sequence of therapy using FOLFIRINOX and nabpaclitaxel + gemcitabine in metastatic pancreatic ductal adenocarcinoma →

Baron, K, Nevala-Plagemann, C, Moser, JC, Halland, B, Wang, X, Garrido-Laguna, I

January 2020

Abstract

ASCO GI Symposium

Gemcitabine and nab-paclitaxel in older adults with metastatic pancreatic cancer: are two doses per cycle enough? →

Winer, A, Handorf, E, Dotan, E

January 2020

Abstract

ASCO GI Symposium

Real-world patterns of care among patients with metastatic pancreatic cancer (mPC) →

O'Reilly, EM, Surinach, A, Wu, Z, Cockrum, P

January 2020

Abstract

ASCO GI Symposium

Impact of prior irinotecan exposure on outcomes of metastatic pancreatic cancer (mPC) patients →

O'Reilly, EM, Surinach, A, Dillon, A, Cockrum, P, Yu, KH

January 2020

Abstract

ASCO GI Symposium

Real-world rates of hematology lab abnormalities and associated cost among metastatic pancreatic cancer (mPC) therapeutic regimens →

Dieguez, G, Surinach, A, Mercer, D, Cockrum, P, Kim, GP, Pelizzari, P

January 2020

Abstract

ASCO GI Symposium

Impact of Treatment Sequence on Overall Survival in Metastatic Pancreatic Cancer Patients with Liposomal Irinotecan in the Real-World Setting →

Kim G, Surinach A, Corvino F, Cockrum P

May 2019

Abstract

ISPOR Annual Meeting

Line of Therapy Definition Impacts Analyses of Second-Line Survival in a Metastatic Pancreatic Cancer Electronic Health Record Database →

Fish SM, Flick DE, Swern AS, Jiang R, Jirau-Lucca G, Ondovik MS, Louis CU

January 2019

Abstract

ASCO GI Symposium

Real-World Dosing Patterns of Patients (Pts) With Metastatic Pancreatic Cancer (MPC) Treated With Liposomal Irinotecan (Nal-iri) in US Oncology Clinics →

Ahn D, Barzi A, Miksad RA, Surinach A, Corvino F, Valderrama A, Mamlouk KK, Pulgar SJ, Bekaii-Saab TS

October 2018

Abstract

ESMO Annual Congress

Flatiron-authored

Real World Outcomes of Metastatic Pancreatic Cancer (mPC) Patients (pts) Treated with Liposomal Irinotecan (nal-IRI) in the US →

Barzi A, Miksad RA, Surinach A, Corvino F, Wang S, Torres AZ, Mamlouk KK, Pulgar SJ, Bekaii-Saab TS

June 2018

Abstract

ASCO Annual Meeting

Flatiron-authored

Treatment Patterns and Clinical Outcomes in Patients with Metastatic Pancreatic Cancer Treated with First-Line Nab-Paclitaxel Plus Gemcitabine: Analysis of US Electronic Health Records from the Flatiron Health Database →

Elizabeth D, Li J, Jirau-licca G, Ondovik M, Nifenecker M, Fish S, Liu H, Huang J, Swern A, Louis C

September 2017

Abstract

ESMO Annual Congress

Treatment patterns and clinical outcomes in patients with metastatic pancreatic cancer treated with first-line nab-paclitaxel plus gemcitabine: Analysis of US electronic health records from the Flatiron Health Database →

Flick, ED, Li, JS, Jirau-Lucca, G, Ondovik, MS, Nifenecker, M, Fish, S, Liu, H, Huang, JH, Swern, A, Louis, CU

June 2017

Abstract

ESMO World Congress on Gastrointestinal Cancer

Chemotherapy Use Near End of Life (EOL): Measuring Real World Benchmarks →

Kraut J, Gippetti J, Peterson D, Agarwala V, Revol C, Fessele K, Abernethy AP

March 2017

Abstract

ASCO Quality Care Symposium

Flatiron-authored